SomaLogic

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company was founded by Larry Gold in 2000 and is headquartered in Boulder, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

SomaLogic reports mixed Q4 results, eyes growth through innovation

SomaLogic navigated a mixed financial performance in Q4 2022, focusing on cost management.
The company is strengthening its position in the life sciences sector with innovative products.
Challenges lie in leadership transitions and balancing expenses with growth investments.
Opportunities abound in strategic collaborations, product launches, and market expansion.

SomaLogic reports Q1 revenue growth amid margin challenges

SomaLogic's Q1 performance reflects revenue growth initiatives amidst financial challenges.
Strategic partnerships, expansion plans, and product launches position the company for future growth.
Addressing margin issues and optimizing expenses are critical for achieving profitability and meeting revenue targets.

SomaLogic reports robust Q2 revenue growth, eyes international partnerships

SomaLogic's Q2 2023 performance reflects strong revenue growth and improved cost management, yet challenges persist in achieving profitability.
Strategic strengths include experienced leadership, international expansion, and partnerships driving growth opportunities in the life sciences sector.
Maintaining operational rigor, enhancing margins, and leveraging cash reserves position SomaLogic for sustainable growth and market leadership.

SomaLogic reports revenue growth and strategic merger for future growth

SomaLogic's Q3 2023 performance showed revenue growth and cost management improvements, with a strong cash position. Strategic partnerships and merger offer growth opportunities.
Challenges include revenue decline on a GAAP basis and ongoing EBITDA losses. Opportunities lie in new indications, geographic expansion, and biopharma performance drivers.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOULDER, Colo., April 20, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce First Quarter 2023 Financial Results on May 11, 2023

SomaLogic, Inc. (NASDAQ:SLGC ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Troy Cox - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Adam Taich - EVP, Life Sciences Business Unit Conference Call Participants Dan Brennan - Cowen Kyle Mikson - Canaccord Genuity Operator Welcome to SomaLogic's Fourth Quarter and Full Year 2022 Earnings Call. All participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript

SomaLogic, Inc. (SLGC) delivered earnings and revenue surprises of 0% and 21.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SomaLogic, Inc. (SLGC) Reports Q4 Loss, Tops Revenue Estimates

BOULDER, Colo., March 28, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter and year ended December 31, 2022 and announced a management transition, as well as the appointment of four new members to the Board of Directors.

SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world's largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. This work builds on a successful history of SomaScan® Platform utilization in some of the world's largest population proteomics biobank projects, including the EPIC, MESA, Fenland, Whitehall II, HUNT3, CRIC, COPD Gene, Spiromics, deCODE and ARIC datasets.

Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples

BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results

BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company. SomaLogic will become the sole provider of high-plex proteomics technology to G42. This initiative spans the United Arab Emirates (UAE) and Kingdom of Saudi Arabia (KSA). As part of the agreement between the two entities G42 will be the first certified site in the Middle East.

SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare

Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific Time Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific Time

SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates

BOULDER, Colo., Dec. 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference

TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan. The new site will offer the 7,000-plex SomaScan® Assay in their labs and provide SomaScan data to their customers. By becoming a SomaLogic Certified Site, FonesLife can now run assays on SomaLogic's SomaScan Platform—the largest commercially available proteomic platform—and accelerate their own research and provide additional opportunities to utilize the industry-leading platform in the Asia-Pacific region.

FonesLife offers the 7,000-plex SomaScan® Platform as Japan's first SomaLogic™ Certified Site

BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) --  SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which will allow institutions around the world to run the 7,000-plex SomaScan® Assay in their own labs. By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic's SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as a service provider. SomaLogic Certified Sites receive support services, on-site training and equipment servicing.

Proteomics labs worldwide can now access SomaLogic's industry-leading 7,000-plex SomaScan® Assay with the Certified Site program

SomaLogic, Inc. (NASDAQ:SLGC ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Roy Smythe - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Evan Stampler - Stifel Dan Brennan - Cowen Operator Good morning, and welcome to SomaLogic's Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Q3 2022 Earnings Call Transcript

SomaLogic, Inc. (SLGC) delivered earnings and revenue surprises of 10% and 113.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SomaLogic, Inc. (SLGC) Reports Q3 Loss, Tops Revenue Estimates

BOULDER, Colo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today reported financial results for the quarter ended September 30, 2022.

SomaLogic Reports Third Quarter 2022 Financial Results

Ardagh Metal Packaging SA

Bed Bath & Beyond

GrowGeneration Corp

Kinross Gold

Marinus Pharmaceuticals

Nu Holdings

Olaplex Holdings

Opendoor

Redfin

More penny stocks with unusual options activity right now. The post 10 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

10 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

SomaLogic and prominent research partners will lead five sessions about CVD and other leading causes of death SomaLogic and prominent research partners will lead five sessions about CVD and other leading causes of death

SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease

BOULDER, Colo., Oct. 27, 2022 (GLOBE NEWSWIRE) -- In a recent paper published earlier this month in Nature Scientific Reports, researchers at the National Institutes of Health conducted what may be the largest technical assessment to date of the 7K SomaScan® Platform to measure its performance and to support the platform's growing community of users. The researchers found the platform's extensive proteome coverage, sensitivity and consistently low variability to be particular strengths, and describe these strengths as key advantages over other proteomic approaches.

SomaLogic's 7K SomaScan® Platform receives high marks in independent technical assessment by researchers at the National Institutes of Health

BOULDER, Colo. and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will host a corresponding audio webcast beginning at 8:30 a.m. ET.

SomaLogic to Announce Third Quarter 2022 Financial Results

BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022.

SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

BOULDER, Colo., Sept. 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that Chief Medical Officer Steve Williams, M.D., Ph.D., has been named a 2022 C-Suite Award winner by the Denver Business Journal. The honorees in the Denver Business Journal's 2022 C-Suite Awards program are executives who were evaluated by a team of third-party judges on the impact they have made on their organizations, industries and the greater community.

SomaLogic's Chief Medical Officer Steve Williams honored with C-Suite Award by the Denver Business Journal

BOULDER, Colo., Sept. 14, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that management will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28.

SomaLogic to Present at the Capital One Spatial Biology & Proteomics Summit

Arcos Dorados Hlds

Coty

Helix Energy Solutions Group

Skillsoft

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling ‘Strong Buy' Stocks Trading Under $10 With Tremendous Upside Potential

SomaLogic, Inc. (SLGC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

SomaLogic, Inc. (SLGC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BOULDER, Colo., Aug. 31, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

SomaLogic to Present at Morgan Stanley 20th Annual Global Healthcare Conference

SomaLogic, Inc. (NASDAQ:SLGC ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Roy Smythe - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Conference Call Participants Dan Brennan - Cowen Brandon Couillard - Jefferies Dan Arias - Stifel Kyle Mikson - Canaccord Operator Good day, and thank you for standing by. Welcome to the SomaLogic's Q2 2022 Earnings Conference Call.

News for SomaLogic Stock (SLGC)